Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Skin Neoplasms × bempegaldesleukin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 3 Melanoma 3 Recurrence 2 Head and Neck Neoplasms 2 Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, B-Cell 1 Leukemia 1 Kidney Neoplasms 1 Glioma 1 Ependymoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1

Interventions

Cyclophosphamide 11 fludarabine 8 aldesleukin 8 fludarabine phosphate 6 pembrolizumab 5 Nivolumab 4 Ipilimumab 4 Interleukin-2 4 dabrafenib 2 Vemurafenib 2 Biopsy 2 Aminolevulinic Acid 2 varlilumab 1 trametinib 1 tilsotolimod 1 spartalizumab 1 sotigalimab 1 sonidegib 1 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 glembatumumab vedotin 1 eprenetapopt 1 encorafenib 1 cemiplimab 1 cabozantinib 1 binimetinib 1 bempegaldesleukin 1 abobotulinumtoxinA 1 X-Rays 1 Tranexamic Acid 1 Tacrolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated

765 enrolled 13 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡